BRAINAURORA-B (06681) has become a strategic partner of the Beijing Advanced Brain-Machine Interface Research Institute, jointly promoting the clinical translation of key technologies in brain-machine interfaces.

BRAINAURORA-B(06681) announced that the group has officially become a strategic partner of the Beijing Frontiers Brain-Machine Interface Research Institute in the near future. On March 27, 2026, the company's subsidiary, Zhejiang Brain Dynamics Aurora Medical Technology Co., Ltd., signed a strategic cooperation agreement with the Beijing Frontiers Brain-Machine Interface Research Institute on site. Brain-machine interface technology has entered a new stage of comprehensive transformation. With the inclusion of brain-machine interface in the country's "14th Five-Year Plan" as a key development direction, and the relevant arrangements in the 2026 government work report, the brain-machine interface industry is ushering in a period of rapid development. Against this backdrop, the establishment of the Beijing Frontiers Brain-Machine Interface Research Institute marks a new stage in China's brain-machine interface field, with clinical deep demand driving, and systemic transformation throughout the entire chain. The institute faces the urgent needs of more than 100 million patients with neurological diseases in China, striving to solve the current structural weaknesses of "technology first, scene lagging". Collaborative innovation among industry, academia, research, and medicine is an inevitable choice. Medical rehabilitation has been identified as the core track for the implementation of brain-machine interface technology. Relying on the top clinical resources of Xuanwu Hospital of Capital Medical University, the construction of an innovative ecosystem that integrates medicine and industry, and promotes the clinical transformation of brain-machine interface technology and forms a critical path from data to validation. As a veteran participant in the Chinese cognitive impairment digital therapy market, the group has accumulated rich experience in the integration of brain science and AI technology, and its cooperation with the research institute will effectively promote the clinical validation and industrial implementation of core technologies. Through joint research and clinical validation, both parties will rely on the six common support platforms established by the research institute to conduct in-depth cooperation in areas such as the construction of multimodal neurological disease databases, development of neurophysiological big models, and clinical validation of related brain-machine interface products. Building an innovative ecosystem throughout the entire chain, the group will leverage its own technological accumulation and productization capabilities in the field of cognitive impairment digital therapy, and collaborate deeply with the research institute's scientific research and clinical resources. Together, they will create a complete chain from data to algorithm, from validation to product, accelerating the clinical transformation process of brain-machine interface technology. Responsibilities of the group (Brain Dynamics Aurora): Utilize its technological advantages in the field of digital therapy and artificial intelligence to participate in joint research and development in key areas such as neurophysiological big models. Combining clinical needs, promote the product transformation and application verification of relevant technologies. Collaborate with the research institute and clinical institutions to explore innovative application models of brain-machine interface technology in the diagnosis and treatment of cognitive impairments. Responsibilities of the partner (Beijing Frontiers Brain-Machine Interface Research Institute): Provide cutting-edge scientific research support and clinical resources in the field of brain-machine interface. Relying on Xuanwu Hospital and a multi-center network, organize clinical research and validation work. Build common technological platforms to provide infrastructure support for collaborative research and development. Both parties agree to jointly promote the research and clinical validation of key products in the field of brain-machine interface. The group will work with the research institute and other strategic partner enterprises to jointly advance the research and development of key directions such as multi-modal neurological disease databases, neurophysiological big models, and closed-loop neural control brain-machine interface products, building an innovative ecosystem that integrates medicine and industry. The Board believes that this strategic cooperation is in line with the group's long-term development strategy and will help the group make full use of top clinical resources, deepen its technological accumulation and product layout in the field of brain-machine interface and cognitive impairments. Through complementary advantages with the research institute, the group is expected to further strengthen its leading position in the industry and create long-term value for shareholders.